BCL-XL-specific inhibitors—including WEHI-539 [60], A-115546360, and A-133185261—have also been developed to target cancer types that depend on BCL-XL for survival with reduced toxicity relative to ABT-263. The gene discussed is BCL2L1; the disease is cancer.